[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000024765A8 - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding dna fragments and uses thereof

Info

Publication number
WO2000024765A8
WO2000024765A8 PCT/CA1999/000992 CA9900992W WO0024765A8 WO 2000024765 A8 WO2000024765 A8 WO 2000024765A8 CA 9900992 W CA9900992 W CA 9900992W WO 0024765 A8 WO0024765 A8 WO 0024765A8
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nos
dna fragments
corresponding dna
chlamydia antigens
Prior art date
Application number
PCT/CA1999/000992
Other languages
French (fr)
Other versions
WO2000024765A3 (en
WO2000024765A2 (en
Inventor
Andrew D Murdin
Raymond P Oomen
Joe Wang
Original Assignee
Aventis Pasteur
Andrew D Murdin
Raymond P Oomen
Joe Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Andrew D Murdin, Raymond P Oomen, Joe Wang filed Critical Aventis Pasteur
Priority to JP2000578335A priority Critical patent/JP2002530052A/en
Priority to CA002348827A priority patent/CA2348827A1/en
Priority to AU12541/00A priority patent/AU1254100A/en
Priority to EP99955602A priority patent/EP1129202A2/en
Priority to MXPA01004291A priority patent/MXPA01004291A/en
Publication of WO2000024765A2 publication Critical patent/WO2000024765A2/en
Publication of WO2000024765A3 publication Critical patent/WO2000024765A3/en
Publication of WO2000024765A8 publication Critical patent/WO2000024765A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100397 (SEQ ID Nos: 1 and 2), CPN100421 (SEQ ID Nos: 3 and 4), CPN100422 (SEQ ID Nos: 4 and 6), CPN100424 (SEQ ID Nos: 7 and 8), CPN100426 (SEQ ID Nos: 9 and 10), CPN100508 (SEQ ID Nos: 11 and 12), CPN100515 (SEQ ID Nos: 13 and 14), CPN100538 (SEQ ID Nos: 15 and 16), CPN100557 (SEQ ID Nos: 17 and 18), CPN100622 (SEQ ID Nos: 19 and 20), CPN100626 (SEQ ID Nos: 21 and 22), CPN100628 (SEQ ID Nos: 23 and 24) and CPN100630 (SEQ ID Nos: 25 and 26).
PCT/CA1999/000992 1998-10-28 1999-10-28 Chlamydia antigens and corresponding dna fragments and uses thereof WO2000024765A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000578335A JP2002530052A (en) 1998-10-28 1999-10-28 Chlamydia antigens and corresponding DNA fragments and uses thereof
CA002348827A CA2348827A1 (en) 1998-10-28 1999-10-28 Chlamydia antigens and corresponding dna fragments and uses thereof
AU12541/00A AU1254100A (en) 1998-10-28 1999-10-28 Chlamydia antigens and corresponding DNA fragments and uses thereof
EP99955602A EP1129202A2 (en) 1998-10-28 1999-10-28 Chlamydia antigenes and corresponding dna fragments and uses thereof
MXPA01004291A MXPA01004291A (en) 1998-10-28 1999-10-28 Chlamydia.

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US10604298P 1998-10-28 1998-10-28
US10604498P 1998-10-28 1998-10-28
US10603998P 1998-10-28 1998-10-28
US10603498P 1998-10-28 1998-10-28
US60/106,034 1998-10-28
US60/106,042 1998-10-28
US60/106,039 1998-10-28
US60/106,044 1998-10-28
US10608798P 1998-10-29 1998-10-29
US10607398P 1998-10-29 1998-10-29
US10607298P 1998-10-29 1998-10-29
US10607498P 1998-10-29 1998-10-29
US60/106,073 1998-10-29
US60/106,074 1998-10-29
US60/106,087 1998-10-29
US60/106,072 1998-10-29
US10658998P 1998-11-02 1998-11-02
US10658798P 1998-11-02 1998-11-02
US10658898P 1998-11-02 1998-11-02
US10703498P 1998-11-02 1998-11-02
US10703598P 1998-11-02 1998-11-02
US60/106,587 1998-11-02
US60/107,035 1998-11-02
US60/106,588 1998-11-02
US60/106,589 1998-11-02
US60/107,034 1998-11-02

Publications (3)

Publication Number Publication Date
WO2000024765A2 WO2000024765A2 (en) 2000-05-04
WO2000024765A3 WO2000024765A3 (en) 2000-11-09
WO2000024765A8 true WO2000024765A8 (en) 2001-12-20

Family

ID=27584510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000992 WO2000024765A2 (en) 1998-10-28 1999-10-28 Chlamydia antigens and corresponding dna fragments and uses thereof

Country Status (5)

Country Link
EP (1) EP1129202A2 (en)
JP (1) JP2002530052A (en)
CA (1) CA2348827A1 (en)
MX (1) MXPA01004291A (en)
WO (1) WO2000024765A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2365196C (en) 1999-03-12 2011-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60036698T2 (en) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto CHLAMYDIA ANTIGENES AND CORRESPONDING DNA FRAGMENTS AND ITS USES
ATE384793T1 (en) 1999-09-20 2008-02-15 Aventis Pasteur CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND THEIR USES
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749382B2 (en) * 1997-06-23 2002-06-27 Loke Diagnostics Aps Novel surface exposed proteins from chlamydia pneumoniae
ATE352624T1 (en) * 1997-11-21 2007-02-15 Serono Genetics Inst Sa CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCES AND POLYPEPTIDES, FRAGMENTS AND APPLICATIONS THEREOF FOR DETECTION, PREVENTION AND CURE

Also Published As

Publication number Publication date
WO2000024765A3 (en) 2000-11-09
CA2348827A1 (en) 2000-05-04
EP1129202A2 (en) 2001-09-05
JP2002530052A (en) 2002-09-17
MXPA01004291A (en) 2003-06-09
WO2000024765A2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
MXPA03002413A (en) B7-like molecules and uses thereof.
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
IL140937A0 (en) Molecules designated ldcam
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO1998018932A3 (en) Novel pesticidal toxins and nucleotide sequences which encode these toxins
WO1998006841A3 (en) Two human nsp-like proteins
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
WO2002030973A8 (en) The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998031795A3 (en) Novel human metallothionein
WO2000024765A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998011234A3 (en) Human protein kinases
WO1998025956A3 (en) Human GTP-binding proteins
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2000032794A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998002456A3 (en) Human c-type lectin
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2002028889A3 (en) Haemophilus influenzae antigens and corresponding dna fragments
WO1998024896A3 (en) Muteins of obese protein
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
ATE318933T1 (en) NUCLEIC ACID FRAGMENTS FOR IDENTIFYING DECHLORINATING BACTERIA
DE59410427D1 (en) Endothelinkonversionsenzym (ece)

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 12541

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 12541/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2348827

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 2000 578335

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004291

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 511403

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999955602

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999955602

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 09830446

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999955602

Country of ref document: EP